Other News To Note
BioLineRx Ltd., of Jerusalem, closed its $15 million private placement with U.S. institutional investors. The company sold about 5.25 million American Depositary Shares (ADSs) at $2.86 per ADS and warrants to purchase up to 2.6 million additional ADSs at an exercise price of $3.57 each, netting BioLineRx around $14.1 million. Roth Capital Management LLC acted as sole placement agent. In other news, BioLineRx received approval from the Israeli Ministry of Health to begin a Phase II trial of BL-7040 for inflammatory bowel disease.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter